Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses common skin appendage diseases, including their pathophysiology and treatments, but does not report new results.

In this study, PRP combined with minoxidil was found to be more effective in improving hair counts in androgenetic alopecia patients compared to minoxidil alone or with dermaroller, showing significant improvements at both 3 and 5 months.

This study found that the novel IPC analog SIG-1451 may inhibit inflammatory cytokine release in cell-based assays relevant to allergic dermatitis.

In this study, researchers found that alopecia areata is linked to immune cell activation against hair follicle autoantigens and is associated with heart changes and cardiac marker alterations in humans and mice.

This Delphi consensus study provides expert insights into hair aging, aims to enhance diagnostic precision and management of age-related hair changes, and identifies possible new therapeutic targets.

This pilot study found that a novel regimen including NuH Hair led to significant hair growth in male patients with androgenic alopecia, regardless of atopy status, with quicker results when additional treatment components were used.

This review concluded that Unani medicine offers a promising holistic approach to managing androgenetic alopecia by focusing on humoral balance and follicular rejuvenation, but further scientific validation is needed for widespread clinical use.

In this cross-sectional study, researchers observed that individuals with early-onset androgenetic alopecia showed significant differences in hair growth parameters and metabolic factors compared to those with normal-onset AGA, suggesting a potential association with metabolic syndrome, though more research is needed to clarify this relationship.

This review discusses the pathogenesis and clinical presentations of alopecia in epidermolysis bullosa patients, noting diverse hair abnormalities and emphasizing the lack of a consensus on its natural history.

This review reports that vitamin D plays an important role in hair follicle development, with a negative correlation observed between serum vitamin D levels and female pattern hair loss, suggesting further research is needed before recommending vitamin D as a treatment.

This review outlines the proposed theories behind the development of alopecia areata, emphasizing the autoimmune process involving lost immune privilege in hair follicles, and stresses the need to pinpoint specific pathogenic mechanisms for potential treatments.

This review discusses the role of stem cells in alopecia pathogenesis, highlighting the differences between scarring and nonscarring types, and reports no new clinical results.

This review article examines the current understanding of frontal fibrosing alopecia, noting its prevalence in different demographics and the roles of genetic and environmental factors in its pathogenesis, while highlighting that treatment approaches remain varied and lack standardization.

This study found that a decrease in estradiol levels in women is associated with increased hair shedding due to weakened anchoring of telogen hairs.

This review discusses how herbal therapies may help manage alopecia and improve quality of life, noting their potential benefits like lower cost and fewer side effects, but emphasizes that more clinical studies are needed for validation.

This study observed that telogen effluvium, or acute hair loss, often occurs 1 to 3 months after SARS-CoV-2 infection, earlier than classic telogen effluvium.

This report describes a case where a sex reassignment patient on estrogen therapy experienced complete hair regrowth on a previously fully alopecic scalp.

This review discusses therapeutic options for androgenetic alopecia, noting that while antiandrogen treatments prevent further hair loss and promote some regrowth, dramatic results are rare.

This article reviews the role of IGF-1 in acne pathogenesis and discusses how diet and smoking may influence insulin/IGF-1 signaling, but reports no new clinical results.

This study found that filamin A plays a crucial role in fibroblasts' ability to sense and respond to mechanical stimuli, significantly affecting wound closure and fibroblast-mediated processes in mice.

This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.

This study suggests that crosstalk between Wnt/β-catenin and TGF-β signaling pathways may contribute to the development of androgenetic alopecia.

This study found that increased levels of PGD2 and prostacyclin and decreased levels of PGE2 and PGF2α were associated with baldness in androgenetic alopecia, suggesting potential targets for treatment.

This study found that in men with androgenetic alopecia, elevated triglycerides were the only factor consistently associated with the condition, suggesting a potential link between AGA and lipid metabolism, although other hormonal, metabolic, and sleep factors were not significantly different after propensity score matching.

Treatments for hair loss vary, but cell-based options may be the future.

This study found that vascular endothelial growth factor may protect hair follicle stem cells from androgen-induced apoptosis in androgenic alopecia patients via the PI3K/Akt pathway.

PGD2 stops hair growth and is higher in bald men with AGA.

In this study, higher scores of HOMA-IR and FIRI suggested that male patients with early-onset androgenetic alopecia may have insulin resistance, although no significant differences in metabolic syndrome were found compared to controls.

This paper proposes a theory explaining how the normal anabolic effects of androgens lead to structural changes and hair follicle miniaturization, contributing to androgenic alopecia.

In this study, PGD2 was shown to increase testosterone production in human keratinocytes through reactive oxygen species, suggesting potential benefits of antioxidants like N-acetyl-cysteine for AGA patients.